Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis.

Paola Di BenedettoPiero RuscittiOnorina BerardicurtiNoemi PanzeraNicolò GraziaMauro Di Vito NolfiBarbara Di FrancescoLuca NavariniAntonio MauriziNadia RucciAnna Maria TetiFrancesca ZazzeroniGiuliana GugginoFrancesco CicciaVincenza DoloEdoardo AlessePaola CiprianiRoberto Giacomelli

Published in: Arthritis research & therapy (2021)

We explored the anti-angiogenic role of tofacitinib, reporting its ability to inhibit in vitro the angiogenic mechanisms of ECs and in vivo the formation of new synovial vessels, occurring in CIA model. These findings suggest that the therapeutic effect of tofacitinib during RA may be also related to its anti-angiogenic activity.

Keyphrases

rheumatoid arthritis
disease activity
ulcerative colitis
ankylosing spondylitis
endothelial cells
vascular endothelial growth factor
emergency department
adverse drug
drug induced